Cue Biopharma's CSU drug meets Phase 2 primary endpoint

Cue Biopharma reported positive topline Phase 2 results for its anti-IgE drug CUE-221 in chronic spontaneous urticaria, supporting a move into Phase 2b/3. The trial met its primary endpoint, showing clear symptom resolution benefits versus placebo with a generally favorable safety profile. Efficacy appeared differentiated versus Xolair, with benefits that persisted beyond the dosing period in the highest-dose group.